206 related articles for article (PubMed ID: 25832557)
21. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
Abed A; Greene MK; Alsa'd AA; Lees A; Hindley A; Longley DB; McDade SS; Scott CJ
Mol Pharm; 2024 Mar; 21(3):1246-1255. PubMed ID: 38334409
[TBL] [Abstract][Full Text] [Related]
22. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
23. Hyperfractionated radiation in children with rhabdomyosarcoma--results of an Intergroup Rhabdomyosarcoma Pilot Study.
Donaldson SS; Asmar L; Breneman J; Fryer C; Glicksman AS; Laurie F; Wharam M; Gehan EA
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):903-11. PubMed ID: 7607964
[TBL] [Abstract][Full Text] [Related]
24. MDM2 Antagonists Counteract Drug-Induced DNA Damage.
Vilgelm AE; Cobb P; Malikayil K; Flaherty D; Andrew Johnson C; Raman D; Saleh N; Higgins B; Vara BA; Johnston JN; Johnson DB; Kelley MC; Chen SC; Ayers GD; Richmond A
EBioMedicine; 2017 Oct; 24():43-55. PubMed ID: 29030058
[TBL] [Abstract][Full Text] [Related]
25. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
26. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
27. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
Studebaker A; Bondra K; Seum S; Shen C; Phelps DA; Chronowski C; Leasure J; Smith PD; Kurmasheva RT; Mo X; Fouladi M; Houghton PJ
Pediatr Blood Cancer; 2015 Oct; 62(10):1768-74. PubMed ID: 25981859
[TBL] [Abstract][Full Text] [Related]
29. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
30. Reactivation of p53 via MDM2 inhibition.
Kim ES; Shohet JM
Cell Death Dis; 2015 Oct; 6(10):e1936. PubMed ID: 26492369
[No Abstract] [Full Text] [Related]
31. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
32. Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 Inhibition.
Lebraud H; Noble RA; Phillips N; Heam K; Castro J; Zhao Y; Newell DR; Lunec J; Wedge SR; Heightman TD
Bioconjug Chem; 2018 Jun; 29(6):2100-2106. PubMed ID: 29851469
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis.
Fang Y; DeMarco VG; Nicholl MB
Cancer Sci; 2012 Jun; 103(6):1090-8. PubMed ID: 22417066
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitization of Adenoid Cystic Carcinoma with MDM2 Inhibition.
Prabakaran PJ; Javaid AM; Swick AD; Werner LR; Nickel KP; Sampene E; Hu R; Ong IM; Bruce JY; Hartig GK; Wieland AM; Canon J; Harari PM; Kimple RJ
Clin Cancer Res; 2017 Oct; 23(20):6044-6053. PubMed ID: 28659312
[No Abstract] [Full Text] [Related]
35. Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Aptullahoglu E; Ciardullo C; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768733
[TBL] [Abstract][Full Text] [Related]
36. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma.
Li JH; Lax SA; Kim J; Klamut H; Liu FF
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):607-16. PubMed ID: 10078646
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
38. In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Thiemann M; Oertel S; Ehemann V; Weichert W; Stenzinger A; Bischof M; Weber KJ; Perez RL; Haberkorn U; Kulozik AE; Debus J; Huber PE; Battmann C
Radiat Oncol; 2012 Mar; 7():52. PubMed ID: 22458853
[TBL] [Abstract][Full Text] [Related]
39. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
40. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
